JP2017536812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536812A5 JP2017536812A5 JP2017520920A JP2017520920A JP2017536812A5 JP 2017536812 A5 JP2017536812 A5 JP 2017536812A5 JP 2017520920 A JP2017520920 A JP 2017520920A JP 2017520920 A JP2017520920 A JP 2017520920A JP 2017536812 A5 JP2017536812 A5 JP 2017536812A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- cell
- composition
- provides
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065138P | 2014-10-17 | 2014-10-17 | |
| US62/065,138 | 2014-10-17 | ||
| US201562151315P | 2015-04-22 | 2015-04-22 | |
| US62/151,315 | 2015-04-22 | ||
| PCT/US2015/056217 WO2016061574A1 (en) | 2014-10-17 | 2015-10-19 | Bipartite and tripartite signaling immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536812A JP2017536812A (ja) | 2017-12-14 |
| JP2017536812A5 true JP2017536812A5 (enExample) | 2018-11-15 |
| JP6821561B2 JP6821561B2 (ja) | 2021-01-27 |
Family
ID=55747478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520920A Active JP6821561B2 (ja) | 2014-10-17 | 2015-10-19 | バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170246278A1 (enExample) |
| EP (2) | EP3489362B1 (enExample) |
| JP (1) | JP6821561B2 (enExample) |
| MA (2) | MA41538A (enExample) |
| WO (1) | WO2016061574A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| PL3212225T3 (pl) * | 2014-10-31 | 2026-03-30 | The Trustees Of The University Of Pennsylvania | Sposoby i kompozycje zmodyfikowanych limfocytów t |
| AU2015380397B2 (en) | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| CN118546961A (zh) * | 2016-08-26 | 2024-08-27 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| EP3518944A4 (en) * | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| CN109880803B (zh) * | 2017-12-06 | 2024-06-07 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| US20190192678A1 (en) * | 2017-12-18 | 2019-06-27 | Novather, Inc. | System and method for the treatment of disease using a hyperspecific modified protein system |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| JP7374434B2 (ja) * | 2018-02-09 | 2023-11-07 | 国立大学法人大阪大学 | 改良されたαβＴ加工細胞製造方法 |
| KR20200130709A (ko) | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| BR112022003553A2 (pt) * | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CN116348485A (zh) | 2020-07-17 | 2023-06-27 | 英研生物(英国)有限公司 | 提供用于过继性细胞疗法的靶向共刺激的受体 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| TW202306997A (zh) | 2021-06-16 | 2023-02-16 | 英商英斯特生物科技有限公司 | 用於在過繼細胞療法中提供標靶共刺激之受體 |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| EP4402161A1 (en) * | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| MX340972B (es) * | 2008-10-08 | 2016-08-02 | Intrexon Corp | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. |
| EP2694640B1 (en) * | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| WO2014172584A1 (en) * | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
-
2015
- 2015-10-18 MA MA041538A patent/MA41538A/fr unknown
- 2015-10-19 WO PCT/US2015/056217 patent/WO2016061574A1/en not_active Ceased
- 2015-10-19 EP EP18214778.5A patent/EP3489362B1/en active Active
- 2015-10-19 US US15/519,742 patent/US20170246278A1/en not_active Abandoned
- 2015-10-19 JP JP2017520920A patent/JP6821561B2/ja active Active
- 2015-10-19 EP EP15850940.6A patent/EP3207147A4/en not_active Withdrawn
- 2015-10-19 MA MA047580A patent/MA47580A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment | |
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| JP6888225B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| IL276593A (en) | Improved methods for producing adoptive cell therapies | |
| ES2671004T3 (es) | Dirección a CD138 en cáncer | |
| IL309526A (en) | TGFBeta signal converter | |
| Ruella et al. | Adoptive immunotherapy for cancer | |
| JP2019535275A5 (enExample) | ||
| JP2021505131A5 (enExample) | ||
| JP2022510207A5 (enExample) | ||
| JP2022548943A5 (enExample) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2019513347A5 (enExample) | ||
| US20170246278A1 (en) | Bipartite and tripartite signaling immune cells | |
| JP2016513458A5 (enExample) | ||
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| JP2016510597A5 (enExample) | ||
| JP2018510160A5 (enExample) | ||
| JP2014512183A5 (enExample) | ||
| Leisegang et al. | T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy | |
| JP2016520302A5 (enExample) | ||
| JP2017503472A5 (enExample) | ||
| JP2015535689A5 (enExample) | ||
| JP2018522567A5 (enExample) |